Table 2.
VICTORIA substudy baseline subject characteristics
| Baseline characteristic | All baseline |
Completed |
P value between complete groups | ||
|---|---|---|---|---|---|
| Placebo | Rimonabant | Placebo | Rimonabant | ||
| Number | 35 | 31 | 27 | 21 | |
| Age (yr) | 54 ± 7 | 55 ± 9 | 54 ± 8 | 56 ± 9 | 0.35 |
| Male/female | 13/22 | 12/20 | 8/17 | 8/12 | |
| BMI (kg/m2) | 35.2 ± 4.1 | 33.5 ± 3.1 | 34.9 ± 4.2 | 32.8 ± 2.4 | 0.18 |
| Total body weight (kg) | 102.5 ± 18.6 | 98.2 ± 15.5 | 100.0 ± 17.7 | 97.6 ± 14.0 | 0.70 |
| Waist circumference (cm) | 114 ± 12 | 110 ± 9 | 113 ± 11 | 108 ± 8 | 0.45 |
| Percent body fat | 43 ± 8 | 44 ± 9 | 44 ± 2 | 43 ± 10 | 0.82 |
| Total body fat (kg) | 43.0 ± 8.7 | 41.2 ± 8.6 | 42.6 ± 1.7 | 40.6 ± 8.6 | 0.42 |
| Visceral fat area (cm2) | 193 (160–253) | 184 (165–206) | 191 (159–250) | 184 (169–198) | 0.67 |
| sc fat area (cm2) | 458 ± 104 | 415 ± 89 | 466 ± 104 | 407 ± 79 | 0.05 |
| Deep sc fat area (cm2) | 260 ± 83 | 227 ± 73 | 256 ± 78 | 226 ± 63 | 0.13 |
| Fasting blood glucose (mg/dl) | 107 ± 13 | 105 ± 12 | 104 ± 11 | 104 ± 13 | 0.93 |
| Glucose slope (×1000) (mg · kg FFM−1 · min−1/pmol · liter−1) | 7.4 (18.0–13.8) | 12.0 (6.8–16.7) | 8.5 (1.4–14.2) | 13.2 (6.4–20.6) | 0.26 |
| IC50 hepatic glucose suppression (pmol/liter) | 229 (144–257) | 159 (121–208) | 207 (134–263) (n = 26) | 149 (121–197) (n = 21) | 0.05 |
| IC50(palmitate)f (pmol/liter) | 183 (122–249) | 129 (111–158) | 183 (118–243) (n = 20) | 140 (116–167) (n = 19) | 0.05 |
| IC50(palmitate) (pmol/liter) | 152 (104–209) | 113 (99–150) | 148 (92–202) (n = 22) | 115 (95–151) (n = 20) | 0.13 |
| Baseline RER | 0.77 ± 0.06 | 0.78 ± 0.06 | 0.76 ± 0.06 | 0.78 ± 0.06 | 0.33 |
| Low insulin rate RER | 0.78 ± 0.05 | 0.79 ± 0.05 | 0.77 ± 0.05 | 0.79 ± 0.06 | 0.12 |
| High insulin rate RER | 0.82 ± 0.06 | 0.84 ± 0.07 | 0.82 ± 0.06 | 0.85 ± 0.07 | 0.16 |
| BMR (kcal/24 h) | 2747 ± 523 | 2616 ± 538 | 2715 ± 539 | 2591 ± 489 | 0.27 |
| Adiponectin (μ g/ml) | 5.13 (4.14–6.51) | 6.54 (3.97–7.45) | 5.43 (4.29–6.03) | 6.5 (3.85–7.31) | 0.69 |
| Fibrinogen (g/liter) | 3.0 ± 0.8 | 3.0 ± 0.7 | 2.9 ± 0.9 | 3.0 ± 0.6 | 0.60 |
| Leptin (ng/ml) | 32.1 (20.8–54.0) | 29.4 (18.6–61.9) | 36.9 (20.8–62.4) | 29.5 (18.3–61.0) | 0.76 |
| Apo B (g/liter) | 0.96 ± 0.29 | 0.97 ± 0.25 | 0.99 ± 0.27 | 0.99 ± 0.26 | 0.94 |
| HDL cholesterol (mmol/liter) | 1.09 (1.01–1.23) | 1.13 (1.03–1.35) | 1.14 (1.04–1.4) | 1.17 (1.07–1.36) | 0.24 |
| LDL cholesterol (mmol/liter) | 3.27 ± 0.90 | 3.56 ± 0.86 | 3.29 ± 0.87 | 3.62 ± 0.96 | 0.26 |
| Total cholesterol (mmol/liter) | 5.30 ± 1.06 | 5.75 ± 0.91 | 5.39 ± 1.00 | 5.85 ± 0.97 | 0.16 |
| Triglycerides (mmol/liter) | 1.83 (1.08–1.83) | 1.97 (1.72–2.26) | 1.89 (1.44–2.15) | 2.00 (1.72–2.26) | 0.20 |
| HbA1c (%) | 5.7 (5.5–5.9) | 5.6 (5.4–5.8) | 5.7 (5.5–5.9) | 5.6 (5.3–5.8) | 0.19 |
Data that are normally distributed are presented as mean ± sd, and data that are not normally distributed are presented as median (interquartile range). Data for all study completers n = 48 unless otherwise stated. HDL, High-density lipoprotein; LDL, low-density lipoprotein.